Unknown

Dataset Information

0

Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity.


ABSTRACT: Although current cancer immunotherapies that target PD-1/PD-L1 immune checkpoint to reinvigorate exhausted T cells have achieved impressive clinical outcomes, only a small proportion of patients respond. New therapeutic targets are therefore needed to be identified to further unleash the anti-tumor potential of T cells and benefit more patients. Galectin-9 (Gal-9), initially identified as a ligand for TIM-3 to induce T cell death, acts as an immunosuppressive regulator in the tumor microenvironment (TME) but its potential as a therapeutic target remains largely elusive. Here we show that antibody neutralization of Gal-9, in combination with inhibition of Ataxia telangiectasia mutated (ATM), a kinase essential for DNA damage response (DDR), is a promising modality for cancer immunotherapy. Genetic depletion of ATM in tumors markedly potentiated anti-Gal-9 therapy in a syngeneic mouse model. Mechanistically, ATM inhibition greatly upregulated Gal-9 expression and secretion in a variety of human and murine tumor cells via the cGAS-STING-interferon β (IFNβ) innate immune pathway. Combination of Gal-9 inhibition with AZD1390, a selective ATM inhibitor currently evaluated in clinical trials, significantly suppressed tumor growth and prolonged survival in multiple syngeneic mouse models, including the poorly-immunogenic LLC lung tumors that do not respond to PD-1/PD-L1 blockade, concomitant with increased T cell infiltration. These results reveal Gal-9 induction via STING/IFNβ signaling as an important mechanism mediating tumor immune escape that could be targeted for cancer immunotherapies, and unveil a novel anti-Gal-9-based combination strategy for cancer immunotherapies in a wide variety of malignancies, including those resistant to PD-1/PD-L1 blockade.

SUBMITTER: Zheng S 

PROVIDER: S-EPMC9909994 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

altmetric image

Publications

Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity.

Zheng Shuang S   Song Jiaming J   Linghu Dongli D   Yang Riyao R   Liu Boning B   Xue Zhen Z   Chen Qihui Q   Liu Chengjie C   Zhong Diansheng D   Hung Mien-Chie MC   Sun Linlin L  

International journal of biological sciences 20230116 3


Although current cancer immunotherapies that target PD-1/PD-L1 immune checkpoint to reinvigorate exhausted T cells have achieved impressive clinical outcomes, only a small proportion of patients respond. New therapeutic targets are therefore needed to be identified to further unleash the anti-tumor potential of T cells and benefit more patients. Galectin-9 (Gal-9), initially identified as a ligand for TIM-3 to induce T cell death, acts as an immunosuppressive regulator in the tumor microenvironm  ...[more]

Similar Datasets

| S-EPMC6437555 | biostudies-literature
| S-EPMC9066214 | biostudies-literature
| S-EPMC4104995 | biostudies-literature
| S-EPMC7927986 | biostudies-literature
| S-EPMC9098186 | biostudies-literature
| S-EPMC10356752 | biostudies-literature
| S-EPMC7295913 | biostudies-literature
| S-EPMC5515246 | biostudies-literature
| S-EPMC5023369 | biostudies-literature
| S-EPMC7470182 | biostudies-literature